Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New prostate cancer test more specific, sensitive than PSA test

17.05.2011
A new test for prostate cancer that measures levels of prostate specific antigen (PSA) as well as six specific antibodies found in the blood of men with the disease was more sensitive and more specific than the conventional PSA test used today, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

The test, called the A+PSA assay, also reduced the rate of false-positives, tests that indicate the presence of cancer when no disease is actually present, said Gang Zeng, an associate professor of urology, a Jonsson Cancer Center researcher and senior author of the study.

"This is a very promising new approach," Zeng said. "Instead of using just one parameter, PSA, to test for prostate cancer, we use multiple parameters that can be measured in a single reaction."

The study appears in the May issue of the peer-reviewed Journal of Translational Medicine.

The conventional PSA test for prostate cancer has been used for nearly 30 years and is not specific enough in delineating between malignancies and non-malignant diseases of the prostate, such as benign prostatic hyperplasia (BPH), an enlarging of the prostate common in aging men that increases PSA levels, Zeng said.

The retrospective study used blood taken before surgery from 131 patients from UCLA, Japan and France with biopsy-confirmed prostate cancers and compared results to blood taken from 121 men with either BPH or prostatitis, an infection or inflammation of the prostate that increases PSA levels. The study focused on six specific prostate-cancer associated antigens – NY-ESO-1, SSX-2,4, XAGE-lb, AMACR, p90 and LEDGF - which are found predominantly in patients with prostate cancer and not in benign prostate conditions.

The A+PSA assay looked simultaneously for PSA and antibodies to the six prostate-cancer associated antigens in a single reaction test done in a laboratory, much like PSA is measured. The new test takes about two hours, again similar to the PSA test. The test results in an index of numbers used to diagnose cancer, with a score of 0 to 0.5 indicating a benign result and 0.5 to 1 indicating the presence of prostate cancer, Zeng said.

In the new test, sensitivity - the percentage of men with prostate cancer who were correctly identified as having a malignancy - was 79 percent compared to the 52 percent found in PSA testing. Specificity - the percentage of healthy men who were correctly identified as not having prostate cancer - was 84 percent compared to the 79 percent found when testing for PSA alone.

The rate of false-positives using conventional PSA testing is 21 percent. With the new A+PSA assay, the false-positive rate is 16 percent, Zeng said.

"Science has improved so much since the PSA test was developed and I think it's time for a more specific and sensitive test to be developed," Zeng said. "I think we have a test that has great potential to improve the diagnosis of prostate cancer. I knew it would be better than the classic PSA test, but I was amazed at how much better it really was in this study."

Dr. Allan Pantuck, an associate professor of urology, Jonsson Cancer Center researcher and a study author, said a more specific and sensitive test for prostate cancer would be a welcome addition to the diagnostic tool box.

"While measuring PSA is useful in identifying men with prostate cancer, some men with prostate cancer have a normal PSA level and small elevations in PSA above normal may be produced both by prostate cancer as well as an enlarged but benign prostate," Pantuck said. "Combining PSA with a panel of tests that measure an individual man's anti-cancer immune response may better identify who has prostate cancer and who can be spared an unnecessary invasive biopsy."

Zeng and his team are working now to adjust and improve the statistical index used in their test to generate the "score." He'd like to do a prospective study that would include the racial, ethnic and age information for each man who provides blood. The test could perhaps be altered for men over a certain age if the antibody levels found in their blood vary. African-American men may also have varying levels of the six antibodies. There also are additional antibodies that could be added to the assay that may improve both the sensitivity and specificity of the test, Zeng said.

"Different men may have different levels of the six antibodies or different antibodies all together based on their race, age and ethnicity," Zeng said. "We want as accurate an assay as we can possibly develop."

Any new prostate cancer test would have to be approved by the U.S. Food & Drug Administration.

The study was funded in part by the Prevent Cancer Foundation, the National Institutes of Health and the National Cancer Institute Early Detection Research Network.

UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2010, the Jonsson Cancer Center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 10 of the last 11 years. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.

Kim Irwin | EurekAlert!
Further information:
http://www.ucla.edu
http://www.cancer.ucla.edu

Further reports about: A+PSA BPH Cancer PSA PSA level PSA test PSA testing prostate cancer

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Bare bones: Making bones transparent

27.04.2017 | Life Sciences

Study offers new theoretical approach to describing non-equilibrium phase transitions

27.04.2017 | Physics and Astronomy

From volcano's slope, NASA instrument looks sky high and to the future

27.04.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>